ATE251613T1 - Pyrimidinonderivate zur behandlung von atheroscleros - Google Patents

Pyrimidinonderivate zur behandlung von atheroscleros

Info

Publication number
ATE251613T1
ATE251613T1 AT99942894T AT99942894T ATE251613T1 AT E251613 T1 ATE251613 T1 AT E251613T1 AT 99942894 T AT99942894 T AT 99942894T AT 99942894 T AT99942894 T AT 99942894T AT E251613 T1 ATE251613 T1 AT E251613T1
Authority
AT
Austria
Prior art keywords
group
bond
formula
ring system
conh
Prior art date
Application number
AT99942894T
Other languages
English (en)
Inventor
Colin Andrew Leach
Stephen Allan Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9818375.9A external-priority patent/GB9818375D0/en
Priority claimed from GBGB9902009.1A external-priority patent/GB9902009D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE251613T1 publication Critical patent/ATE251613T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT99942894T 1998-08-21 1999-08-18 Pyrimidinonderivate zur behandlung von atheroscleros ATE251613T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9818375.9A GB9818375D0 (en) 1998-08-21 1998-08-21 Novel compounds
GBGB9902009.1A GB9902009D0 (en) 1999-01-29 1999-01-29 Novel compounds
PCT/EP1999/006093 WO2000010980A1 (en) 1998-08-21 1999-08-18 Pyrimidinone derivatives for the treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
ATE251613T1 true ATE251613T1 (de) 2003-10-15

Family

ID=26314252

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99942894T ATE251613T1 (de) 1998-08-21 1999-08-18 Pyrimidinonderivate zur behandlung von atheroscleros

Country Status (6)

Country Link
US (1) US6559155B1 (de)
EP (1) EP1105377B1 (de)
JP (1) JP2002523402A (de)
AT (1) ATE251613T1 (de)
DE (1) DE69911980T2 (de)
WO (1) WO2000010980A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145773A0 (en) * 1999-04-13 2002-07-25 Basf Ag Integrin receptor ligands
GB9910079D0 (en) * 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
US6953803B1 (en) 1999-05-01 2005-10-11 Smithkline Beecham P.L.C. Pyrimidine compounds
GB9910378D0 (en) * 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds
ATE333446T1 (de) * 2000-02-16 2006-08-15 Smithkline Beecham Plc Pyrimidin-4-onderivat als ldl-pla2 inhibitor
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
FR2815345B1 (fr) * 2000-10-12 2002-12-13 Servier Lab Nouveaux derives de cyclobutene-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0119793D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
US6939863B2 (en) 2002-01-04 2005-09-06 Wei-Jan Chen Prevention of atherosclerosis and restenosis
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
US20080090852A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US20080090851A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
EA018101B1 (ru) 2007-05-11 2013-05-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способы лечения кожных язв
KR101690390B1 (ko) 2007-05-11 2016-12-27 토마스 제퍼슨 유니버시티 신경변성 질환 및 장애의 치료 및 예방 방법
AU2010232923A1 (en) * 2009-04-03 2011-11-03 Medisyn Technologies, Inc. Compositions for treatment of Alzheimer's disease
CN104478812A (zh) * 2010-12-06 2015-04-01 葛兰素集团有限公司 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物
JP2013544854A (ja) * 2010-12-06 2013-12-19 グラクソ グループ リミテッド 化合物
AU2011340690C1 (en) 2010-12-06 2016-03-10 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp - PLA2
EP2651403B1 (de) 2010-12-17 2020-12-02 Glaxo Group Limited Verwendung von lp-pla2-inhibitoren zur behandlung und vorbeugung von augenerkrankungen
US8975400B2 (en) 2011-07-27 2015-03-10 Glaxo Group Limited 2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors
CN103827118B (zh) * 2011-07-27 2016-03-09 葛兰素集团有限公司 双环嘧啶酮化合物
WO2013014185A1 (en) 2011-07-27 2013-01-31 Glaxo Group Limited Bicyclic pyrimidone compounds
CN105008365B (zh) 2013-01-25 2017-03-15 葛兰素史密斯克莱知识产权发展有限公司 化合物
EP2948452B1 (de) 2013-01-25 2017-08-09 GlaxoSmithKline Intellectual Property Development Limited Auf 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h-)-on basierende lipoprotein-assoziierte phospholipase-a2 (lp-pla2)-inhibitoren
KR20150108896A (ko) 2013-01-25 2015-09-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Lp-pla2의 억제제로서의 비시클릭 피리미돈 화합물
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2021089032A1 (zh) 2019-11-09 2021-05-14 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145546A (en) 1975-10-02 1979-03-20 Smith Kline & French Laboratories Limited 4-Pyrimidone compounds
US4154834A (en) 1975-12-29 1979-05-15 Smith Kline & French Laboratories Limited Substituted isocytosines having histamine H2 -antagonist activity
US6417192B1 (en) * 1997-11-06 2002-07-09 Smithkline Beecham P.L.C. Pyrimidinone compounds and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
JP2002523402A (ja) 2002-07-30
EP1105377B1 (de) 2003-10-08
DE69911980T2 (de) 2004-09-09
US6559155B1 (en) 2003-05-06
EP1105377A1 (de) 2001-06-13
DE69911980D1 (de) 2003-11-13
WO2000010980A1 (en) 2000-03-02

Similar Documents

Publication Publication Date Title
ATE251613T1 (de) Pyrimidinonderivate zur behandlung von atheroscleros
ES2196396T3 (es) Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa.
DE69823344D1 (de) Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen
ATE37375T1 (de) Phosphonyl-hydroxyacyl-aminosaeure-derivate und ihre verwendung als antihypertensiva.
CY1105091T1 (el) Αντικατεστημενες ενωσεις 2-αρυλοβενζαζολιου και η χρηση τους σαν παραγοντες κατα των ογκων
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
ATE86247T1 (de) 3-indolpyruvsaeure-derivate und deren verwendung als arznemittel.
TR199800436A2 (xx) Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�.
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
TR199900856T2 (xx) Bron�la ilgili terapi maddeleri olarak benzonaftiridinler
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
BG105112A (en) Agents with antidepressive effect
DE69232929D1 (de) Saccharinderivate als proteolytische Enzyminhibitoren
TR200002542T2 (tr) Meta-azasiklik amino benzoik asit bileşikleri ve bunların integrin antagonistleri olan türevleri
DE69815311D1 (de) Substituierte derivate von benzosulphonamiden als hemmer des enzym cyclooxygenase ii
MX9800186A (es) Derivados de azetidinona para el tratamiento de ateroesclerosis.
TR200000907T2 (tr) Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri.
ATE277031T1 (de) Dihydrobenzofuranderivate verwendbar als entzündungshemmende mittel
FI973111A (fi) Substituoidut fenyyliyhdisteet endoteliiniantagonisteina
ATE86994T1 (de) Ornithin-derivate und deren verwendung als inhibitoren von methothrexat resistenten zellen.
NO983527L (no) Dihydrobenzofuran og relaterte forbindelser anvendelig som anti-inflammatoriske midler
DE69629282D1 (de) Verwendung eines pyruvatdehydrogenaseaktivators zur behandlung der ischämie in gliedern
DE69917445D1 (de) Reinigung von carboxaldehyd
IT1261662B (it) Derivati xantonici, loro preparazione ed attivita'

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties